Veracyte Stock

Veracyte EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Veracyte (VCYT) as of Aug 19, 2026 is 35.27. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 162.00 — a change of -78.23% (lower).

EV/EBIT

35.27

YoY

-78.23%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Veracyte is 2026 35.27 . EV/EBIT (Enterprise Value to EBIT) of Veracyte was 2025 162.00 . It decreases by -78.23% lower compared to the previous year.

The Veracyte EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-90.62 base
Jan 1, 2020
-80.24 base
Jan 1, 2021
-35.75 base
Jan 1, 2022
-41.49 base
Jan 1, 2023
-23.44 base
Jan 1, 2024
196.03 base
Jan 1, 2025
46.21 base
Jan 1, 2026 (e)
11.53 base
YEARPRICE-TO-EBIT
2026 est 11.53
2025 46.21
2024 196.03
2023 -23.44
2022 -41.49
2021 -35.75
2020 -80.24
2019 -90.62
2018 -24.36
2017 -8.06
2016 -8.58
2015 -5.95
2014 -7.50
2013 -8.73
2012 -
2011 -
Access this data via the Eulerpool API

Veracyte Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Veracyte's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Veracyte's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Veracyte's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Veracyte grows earnings faster than its peers.

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

EV/EBIT (Enterprise Value to EBIT) of Veracyte is 35.27 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Veracyte changed from 162.00 to 35.27, representing a -78.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Veracyte since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Veracyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Veracyte

All Key Metrics — Veracyte